Aptus Pharma IPO
Closed SMEAlready have an account? Apply now
Aptus Pharma IPO details
Schedule of Aptus Pharma
| Issue open date | 23 Sep 2025 |
| Issue close date | 25 Sep 2025 |
| UPI mandate deadline | 25 Sep 2025 (5 PM) |
| Allotment finalization | 26 Sep 2025 |
| Refund initiation | 29 Sep 2025 |
| Share credit | 29 Sep 2025 |
| Listing date | 30 Sep 2025 |
| Mandate end date | 10 Oct 2025 |
| Lock-in end date for anchor investors (50%) | 26 Oct 2025 |
| Lock-in end date for anchor investors (remaining) | 25 Dec 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Aptus Pharma
Aptus Pharma is a Gujarat-based pharmaceutical company incorporated in 2010, engaged in marketing and distribution of finished pharmaceutical formulations. The company operates through a contract manufacturing model without owning manufacturing facilities, partnering with seven manufacturing units. Aptus offers a diverse range of pharmaceutical products across therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, and wellness products. Products are available in various dosage forms including tablets, capsules, syrups, injections, ointments, and drops.
Financials of Aptus Pharma
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹ 13.02 crores |
| Fresh Issue | ₹ 13.02 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capital expenditure | 1.63 (12.5%) |
| Working capital requirements | 8.00 (61.5%) |
| General Corporate Purposes and miscellaneous | 3.39 (26%) |
Strengths
- Established presence in pharmaceutical marketing and distribution since 2010
- Diverse product portfolio across multiple therapeutic categories and dosage forms
- Partnership network with seven manufacturing units providing operational flexibility
- Experienced promoter group with pharmaceutical industry expertise
Risks
- Complete dependence on contract manufacturers creating supply chain vulnerabilities
- Lack of manufacturing facilities limiting control over production quality and costs
- Regulatory compliance risks across multiple therapeutic categories and formulations
- Dependence on key manufacturing partners for business continuity and product quality
Allotment Status for Aptus Pharma
To check your allotment status – click here.
Subscription Figures for Aptus Pharma
As per media reports (Link), the Grey Market Premium (GMP) of Aptus Pharma is reported at ₹7 over the IPO price. This metric is not reliable, and to track IPO interest, it is better to check subscription numbers published by exchanges, which are considered more reliable indicators.
Subscription numbers as of 5:00 PM on September 25, 2025:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 3.52 | 4.36x | 1.24x |
| NII | 2.66 | 76.48 | 28.75x |
| Retail | 6.20 | 194.88 | 31.43x |
| Total | 12.38 | 275.72 | 22.27x |